This
is another post in a series detailing the selection of antidepressant
medication. Use the "Antidepressants" link in the
"Categories"
part of the sidebar to find the other posts in the series.In this post, I am sort of assuming that the reader has read the previous posts, or has an adequate fund of general knowledge on the subject.
Bupropion
is not a member of a family. Most antidepressants can be
placed
in a family of drugs that share similar properties, but there is no
other drug like it, as of the time of this writing. It is
sometimes referred to as a norepinephrine-dopamine
reuptake inhibitor
(NDRI) but in my mind it does not make sense to give it a class name if
there is only one member of the class. (It is rumored that an active
metabolite, hydroxybupropion, may be marketed eventually, but
development is on hold at the present time.)Bupropion, then, is unique. For that reason, it deserves particular attention...
The
most significant thing about bupropion is that it has no effect on
serotonin. Therefore, many the adverse effects associated
with SSRIs are absent. In particular, bupropion has a very
low likelihood of causing sexual dysfunction. That is a pretty big
plus, and that fact alone probably accounts for the popularity of the
drug.
Also, there is little if any risk of weight gain or sedation, and very little risk of dry mouth or constipation. These properties make bupropion very different from the tricyclic antidepressants.
There are some relative disadvantages, naturally. Bupropion has no antiobsessive effect, and for most people it has little beneficial effect on any kind of anxiety. Unlike SSRIs, TCAs, and MAOIs, it is not good for panic disorder. It is not effective for social phobia. Some people seem to get some benefit for generalized anxiety. In general, though, bupropion is not helpful for anxiety disorders for most people.
The most commonly seen troublesome adverse effects are insomnia and tremor; some people feel restless or jittery from it.
There is virtually no abuse potential. There are sporadic reports of people crushing the tablets and snorting the powder, but for the vast majority of people this does nothing that is desirable.
The main risk associated with bupropion is that it lowers the seizure threshold. That is, it increases the probability of seizures. At normal doses this effect is not clinically significant, so long two conditions are met. The person should not have any predisposition to having seizures, and the person should not be taking any other substance that would either lower the seizure threshold significantly, or delay the metabolism of bupropion significantly.
The metabolism is a bit complex, but by and large the clinically significant interactions occur with the cytochrome P450 enzyme, CYP2B6. This is a known effect of many antiretroviral drugs, and some antidepressants: sertraline, paroxetine, norfluoxetine (the active metabolite of fluoxetine), and fluvoxamine.
In actual practice, it is common for bupropion to be administered along with some of the drugs that inhibit CYP2B6, but it is a good idea to be cautious with these drug combinations. The modern antidepressants that are least likely to cause this interaction are citalopram, escitalopram, and venlafaxine.
Clinical conditions that present an elevated risk from the lowering of seizure threshold include epilepsy, traumatic brain injury, and eating disorders.
Bupropion is sometimes used to treat conditions other than depression. The most established such use is the treatment of nicotine dependence. For reasons that are clear only to FDA bureaucrats, bupropion is packaged and labeled separately for this purpose, as Zyban. Zyban has exactly the same active ingredient as Wellbutrin and all generic forms of bupropion.
Some of the neuroscience fans who might be reading this might wonder why a drug that inhibits reuptake of dopamine and norepinephrine would have anything to do with nicotine dependence. The answer is that bupropion also acts as an antagonist for certain nicotine receptors (PDF link).
Some persons have advocated the use of bupropion for treatment of ADHD, and for psychostimulant (cocaine, amphetamine, methamphetamine) abuse. These uses are not very well supported.
Bupropion is also being studied in combination with naltrexone for the treatment of obesity. Contrave (TM) is a combination for this purpose, currently in Phase II trials by Orexigen Therapeutics. Incidentally, IntelGenx Technologies is developing a combination of bupropion and mecamylamine, QuitPak, as a sort of supercharged Zyban for smoking cessation.
So, enough of the background. What does this all mean when it comes to the issue of selection of an antidepressant?
Bupropion is particularly good for people who have, or wish to avoid, sexual dysfunction,weight gain, or somnolence caused by other antidepressants.
Bupropion could be good choice for people who want to quit smoking, have ADHD, or who have a problem with dependence on stimulants. Personally, I have not been impressed by its effect on ADHD. However, everyone is different, and if there is a chance to use one drug (rather than two) for two conditions, it is good to try to do so.
Bupropion is not particularly good for people who want to treat both anxiety and depression with one medication. It should be used with caution, if at all, in people who have risk factors for seizures, or who are unavoidably taking a drug that interacts negatively with bupropion.
Also, there is little if any risk of weight gain or sedation, and very little risk of dry mouth or constipation. These properties make bupropion very different from the tricyclic antidepressants.
There are some relative disadvantages, naturally. Bupropion has no antiobsessive effect, and for most people it has little beneficial effect on any kind of anxiety. Unlike SSRIs, TCAs, and MAOIs, it is not good for panic disorder. It is not effective for social phobia. Some people seem to get some benefit for generalized anxiety. In general, though, bupropion is not helpful for anxiety disorders for most people.
The most commonly seen troublesome adverse effects are insomnia and tremor; some people feel restless or jittery from it.
There is virtually no abuse potential. There are sporadic reports of people crushing the tablets and snorting the powder, but for the vast majority of people this does nothing that is desirable.
The main risk associated with bupropion is that it lowers the seizure threshold. That is, it increases the probability of seizures. At normal doses this effect is not clinically significant, so long two conditions are met. The person should not have any predisposition to having seizures, and the person should not be taking any other substance that would either lower the seizure threshold significantly, or delay the metabolism of bupropion significantly.
The metabolism is a bit complex, but by and large the clinically significant interactions occur with the cytochrome P450 enzyme, CYP2B6. This is a known effect of many antiretroviral drugs, and some antidepressants: sertraline, paroxetine, norfluoxetine (the active metabolite of fluoxetine), and fluvoxamine.
In actual practice, it is common for bupropion to be administered along with some of the drugs that inhibit CYP2B6, but it is a good idea to be cautious with these drug combinations. The modern antidepressants that are least likely to cause this interaction are citalopram, escitalopram, and venlafaxine.
Clinical conditions that present an elevated risk from the lowering of seizure threshold include epilepsy, traumatic brain injury, and eating disorders.
Bupropion is sometimes used to treat conditions other than depression. The most established such use is the treatment of nicotine dependence. For reasons that are clear only to FDA bureaucrats, bupropion is packaged and labeled separately for this purpose, as Zyban. Zyban has exactly the same active ingredient as Wellbutrin and all generic forms of bupropion.
Some of the neuroscience fans who might be reading this might wonder why a drug that inhibits reuptake of dopamine and norepinephrine would have anything to do with nicotine dependence. The answer is that bupropion also acts as an antagonist for certain nicotine receptors (PDF link).
Some persons have advocated the use of bupropion for treatment of ADHD, and for psychostimulant (cocaine, amphetamine, methamphetamine) abuse. These uses are not very well supported.
Bupropion is also being studied in combination with naltrexone for the treatment of obesity. Contrave (TM) is a combination for this purpose, currently in Phase II trials by Orexigen Therapeutics. Incidentally, IntelGenx Technologies is developing a combination of bupropion and mecamylamine, QuitPak, as a sort of supercharged Zyban for smoking cessation.
So, enough of the background. What does this all mean when it comes to the issue of selection of an antidepressant?
Bupropion is particularly good for people who have, or wish to avoid, sexual dysfunction,weight gain, or somnolence caused by other antidepressants.
Bupropion could be good choice for people who want to quit smoking, have ADHD, or who have a problem with dependence on stimulants. Personally, I have not been impressed by its effect on ADHD. However, everyone is different, and if there is a chance to use one drug (rather than two) for two conditions, it is good to try to do so.
Bupropion is not particularly good for people who want to treat both anxiety and depression with one medication. It should be used with caution, if at all, in people who have risk factors for seizures, or who are unavoidably taking a drug that interacts negatively with bupropion.
Comments
It is true, is it not, that Wellbutrin is increasingly prescribed in combination with an SSRI? I have heard talk of "Well-loft," Wellzac," "Wellapro" etc. Is this a good thing?
Posted by: CCP | July 3, 2007 2:06 PM
There's good evidence for bupropion augmentation in the level 2 reports for Star*D trials.
Do you see that bupropion is one of the most misused antidepressants prescribed by well-meaning non-psychiatrists? Family docs (and even OB folk) seemed strangely partial to it (expressedly for lack of sexual side effects) as monotherapy, despite presence of comorbid anxiety for which, as you point out, we don't have positive evidence.
Posted by: Garrett | July 3, 2007 3:28 PM
I don't have access to data that would tell us if prescriptions for combinations of SSRIs and Wellbutrin are increasing, but I can say that I have the subjective impression that it is so.
It isn't possible to say if it is good, in general. You would have to look at each instance and decide in each case whether the combination makes sense.
I can make a couple of general comments, though. I can say that it is common for persons with depression to be treated inadequately; that is, they are given treatments that result in improvement (response), without attaining remission. If the use of these combinations is an indication that the physicians are making more of an effort to treat until remission in achieved, then it is good. Or, if it is a sign that the physicians are sensitive to the patient's reports of adverse effects, then it is good.
On the other hand, if there are cases of polypharmacy resulting from uninformed prescribing, it is bad. I would be particularly concerned about the possibility that some of these prescriptions could be written without adequate regard for pharmacokinetic drug interactions.
Posted by: Joseph j7uy5 | July 3, 2007 3:43 PM
If Wellbutrin is being increasingly prescribed, either on its own or as augmentation, perhaps physicians are preferring it in cases where they are treating chain-smoking clinical depressives who want or need to quit smoking. Just a thought.
Posted by: Dirk Hanson | July 6, 2007 12:27 AM
My husband was given Wellbutrin to quit smoking and somehow it made him very irritable.He definitely experienced sexual dysfunction while on it, as well as difficulty urinating. My father, who's stupidly and scarily aggressive if he's not on antidepressants, said he had a similar experience when his doc tried Wellbutrin on him. I was on Wellbutrin for like 3 years and I never had adverse effects. I was switched like a year ago to another drug due to a convulsive syncope (due to lowered sugar levels according to my neurologist), and rather miss the non-drowsiness of Wellbutrin.
Posted by: Brigit | August 1, 2007 6:56 PM
thankss have access to data that would tell us if prescriptions for combinations of SSRIs and Wellbutrin are increasing.
Posted by: kral oyun | March 5, 2008 5:34 AM
If Wellbutrin is being increasingly prescribed, either on its own or as augmentation, perhaps physicians are preferring it in cases where they are treating chain-smoking clinical depressives who want or need to quit smoking. Just a thought.
Posted by: mirc | March 14, 2008 5:11 PM
Thank You. Have access to data that would tell us if prescriptions for combinations of SSRIs and Wellbutrin are increasing.
Posted by: İyinet webmaster forumu 2008 seo yarışması | March 20, 2008 2:41 PM
It is true, is it not, that Wellbutrin is increasingly prescribed in combination with an SSRI? I have heard talk of "Well-loft," Wellzac," "Wellapro" etc. Is this a good thing? THANK YOU.
Posted by: davetiye | March 27, 2008 12:23 PM
There's good evidence for bupropion augmentation in the level 2 reports for Star*D trials. thabk you
Posted by: Dijital Fotoğraf Makinesi | April 7, 2008 1:40 PM
eyvallah saolun harbiden on numara bi çalışma olmuş. Ben sadece benim işime yarayan kısmındayım. Link eklememdeki amaç belli, sebep belli. : ) Neyse çok gevezelik yaptım kendinize iyi bakın. Thanks you very nice..
Posted by: Prefabrik | June 10, 2008 11:01 AM
Thanks Very good sites
Posted by: mp4 | June 16, 2008 9:04 AM
Well, we started again… All the time I think I know ALL about css … somebody destroy my idea. Anyways, thanks, is good to know that I didn’t know some clinches.
Posted by: lida | August 14, 2008 5:42 AM
Very nice. Thanks you. Family docs (and even OB folk) seemed strangely partial to it (expressedly for lack of sexual side effects) as monotherapy, despite presence of comorbid anxiety for which, as you point out, we don't have positive evidence.
Posted by: Book | October 10, 2008 8:02 AM
There's good evidence for bupropion augmentation in the level 2 reports for Star*D trials. thabk you
Posted by: islami sohbet | June 13, 2009 1:49 AM
Thank You. Have access to data that would tell us if prescriptions for combinations of SSRIs and Wellbutrin are increasing.
Posted by: paylasonline | June 15, 2009 11:54 PM
Thanks you too much, i am waiting to new version!
Posted by: çelik çatı | July 15, 2009 1:34 PM
But you can create a couple of general comments. I treat the depression that poor people are common, so this treatment is given why this improvement (response) without achieving remission. This combination is an indication that the doctors are making use of an effort to get more, this is good as well for treatment remission. Or, a good sign that the patient reports of adverse effects of this doctor is sensitive.
Posted by: prefabrik | August 7, 2009 4:55 AM